Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest MiMedx Group Inc. Stories

2013-07-03 12:23:45

MARIETTA, Ga., July 3, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has filed a shelf registration statement on Form S-3 with the United States Securities and Exchange Commission ("SEC"). The registration statement is intended to provide the Company with flexibility to access the public capital...

2013-07-02 12:30:03

MARIETTA, Ga., July 2, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has been included in the Russell 2000®, the Russell 3000 and the Russell Global Indexes effective at the start of trading on July 1, 2013. Membership in the Russell indexes, which remains in place for one year, means automatic...

2013-06-28 12:24:04

EPIFIX® NOW APPROVED FOR COVERAGE BY SIX OF THE NINE MEDICARE CONTRACTORS MARIETTA, Ga., June 28, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that the Company's wound care allograft, EpiFix®, received reimbursement coverage by Medicare Contractor Wisconsin Physician Services (WPS), effective July 1,...

2013-06-26 08:31:27

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, June 26, 2013 /PRNewswire/ -- Today, Wall Street Reports announced new research reports highlighting Stryker Corp. (NYSE: SYK), Techne Corp. (NASDAQ: TECH), Hill-Rom Holdings, Inc. (NYSE: HRC), MiMedx Group, Inc. (NASDAQ: MDXG) and Masimo Corporation (NASDAQ: MASI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings...

2013-06-11 12:29:46

MARIETTA, Ga., June 11, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its receipt of three newly issued patents related to tissue allografts derived from the placenta. The U.S Patent Office has issued to MiMedx® U.S. Patent Number 8,409,626, "Placental Tissue Grafts" with a grant date of April 2, 2013. The U.S....

2013-06-10 12:26:13

MARIETTA, Ga., June 10, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that a randomized controlled trial (RCT) for the Company's EpiFix(R) wound care allograft has been published in the International Wound Journal. Parker H. "Pete" Petit, Chairman and CEO, said, "The results of this clinical trial were...

2013-05-28 12:27:35

KENNESAW, Ga., May 28, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the Jefferies 2013 Global Healthcare Conference in New York. Parker H. "Pete" Petit, Chairman and CEO and Michael J. Senken, Chief Financial Officer, are scheduled to present on June 3, 2013 at 1:30 p.m. Eastern Daylight...

2013-05-20 16:26:07

KENNESAW, Ga., May 20, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has secured a revolving line of credit with Bank of America. The revolving line of credit facility, which is secured by the Company's accounts receivable and inventory, allows MiMedx to borrow up to $3.0 million through May 1, 2014. The...

2013-05-01 08:29:46

KENNESAW, Ga., May 1, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NasdaqCM: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the quarter ended March 31, 2013. Highlights of First Quarter 2013 Results include: Revenue exceeded forecast for fifth consecutive quarter Revenue more than triples over first quarter of 2012 Fifth consecutive quarter of...

2013-04-22 16:25:39

MiMedx Common Stock to begin trading on NASDAQ under the symbol "MDXG" on April 25, 2013 KENNESAW, Ga., April 22, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its common stock has been approved for listing on The NASDAQ Capital Market under the ticker symbol "MDXG." Trading on NASDAQ is expected to...